Cargando…
Evaluation of bumetanide as a potential therapeutic agent for Alzheimer’s disease
Therapeutics discovery and development for Alzheimer’s disease (AD) has been an area of intense research to alleviate memory loss and the underlying pathogenic processes. Recent drug discovery approaches have utilized in silico computational strategies for drug candidate selection which has opened t...
Autores principales: | Boyarko, Ben, Podvin, Sonia, Greenberg, Barry, Momper, Jeremiah D., Huang, Yadong, Gerwick, William H., Bang, Anne G., Quinti, Luisa, Griciuc, Ana, Kim, Doo Yeon, Tanzi, Rudolph E., Feldman, Howard H., Hook, Vivian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436590/ https://www.ncbi.nlm.nih.gov/pubmed/37601062 http://dx.doi.org/10.3389/fphar.2023.1190402 |
Ejemplares similares
-
Dysregulation of Neuropeptide and Tau Peptide Signatures
in Human Alzheimer’s Disease Brain
por: Podvin, Sonia, et al.
Publicado: (2022) -
The role of innate immune genes in Alzheimer's disease
por: Griciuc, Ana, et al.
Publicado: (2021) -
3D culture models of Alzheimer’s disease: a road map to a “cure-in-a-dish”
por: Choi, Se Hoon, et al.
Publicado: (2016) -
Human Tau Isoforms and Proteolysis for Production of Toxic Tau Fragments in Neurodegeneration
por: Boyarko, Ben, et al.
Publicado: (2021) -
Cromolyn Reduces Levels of the Alzheimer’s Disease-Associated Amyloid β-Protein by Promoting Microglial Phagocytosis
por: Zhang, Can, et al.
Publicado: (2018)